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Abstract With the recent advances in chemotherapy for
colorectal cancer, the prognosis for patients with metastatic
colorectal cancer has been significantly improved. The
development of the implantable port system has also
enabled patients to receive multiagent chemotherapy with a
more satisfactory quality of life. Historically, chemother-
apy using implantable port systems was begun to obtain an
oncological benefit in the treatment of locoregional cancer.
In the 1950s, there was an increasing interest in perfusion
techniques for the application of chemotherapeutic agents,
such as nitrogen mustard, in the locoregional treatment of
metastatic cancer. Among them, the treatment of liver
metastasis has interested oncologists for many years. On
the other hand, implantable devices were developed during
the intervening decades that have enabled patients with
colorectal cancer with liver metastases to be treated
effectively using hepatic arterial infusion; which became
more common in the 1980s. The treatment of metastatic
colorectal cancer increasingly requires a multimodal
approach and multiple treatment options based not on
convenience, but in terms of personalization and efficacy.
Therefore, it is important to optimize the pharmacokinetics
of chemotherapeutic agents. Implantable port systems for
colorectal cancer patients have been essential for onco-
logical practice, and the importance of these systems will
remain unchanged in the near future.
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Introduction
Over the past several decades, many management changes
in oncology have occurred, especially in chemotherapy for
colorectal cancer (CRC). From the early predominance of
bolus injections of 5-fluorouracil (5-FU), chemotherapy
has made considerable progress for CRC, including the
biochemical modulation of the 5-FU effect by leucovorin,
the development of infused 5-FU/leucovorin regimens and
the introduction of irinotecan and oxaliplatin. Furthermore,
the development of active cytotoxic chemotherapy regi-
mens that incorporate biological targeted agents for meta-
static CRC has significantly improved the survival periods
of patients with metastatic CRC to more than 2 years [1–3].
Therefore, the main aims of modern chemotherapy for
metastatic CRC have become the prolongation of survival
and a better quality of life. In addition, modern chemo-
therapy using various combination regimens has become
widely accepted as implantable port systems and dispos-
able infusion pumps have been developed [4].
Easy-to-handle port systems are currently an important
part of clinical practice in oncology. The history of che-
motherapy using implantable port systems has three
streams: (1) locoregional cancer therapy, (2) drug delivery
and (3) implantable devices (Table 1). In the 1950s, there
was increasing interest in the perfusion and infusion tech-
niques for the application of chemotherapeutic agents, such
as nitrogen mustard, in the locoregional treatment of met-
astatic cancer. Among them, treatment of liver metastasis
has interested oncologists for many years, because it seems
that, although the liver is a primary site of blood-borne
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metastases, it is often the only site of metastatic disease,
especially in patients with CRC. Implantable devices have
been further developed during the last few decades, and
this has enabled patients with CRC with liver metastases to
be treated effectively by locoregional therapy using hepatic
arterial infusion (HAI); which became more common in the
1980s. With several lines of chemotherapy currently
available for metastatic CRC, central venous catheters and
implantable port systems are used worldwide. This article
comprises a historical review of the progress made in
chemotherapy for metastatic CRC from the viewpoint of
the development of implantable port systems. It also dis-
cusses the current and future directions in chemotherapy
for CRC using implantable port systems.
History of locoregional cancer therapy
The first clinical application of cytotoxic chemotherapy for
malignancies can be traced back to the 1940s, with the
introduction of nitrogen mustard [5]. At that time, the
limiting factor in the use of mustard compounds was their
toxic effect on normal tissues. To avoid these systemic
toxic effects, Klopp et al. [6] proposed the use of intra-
arterial cancer chemotherapy with nitrogen mustard in
1950. A suitable technique was developed by utilizing a
method devised for the intra-arterial administration of
heparin [7], and polyethylene tubes were introduced into
the external carotid artery. Next, the locoregional cancer
therapy evolved into regional perfusion utilizing an extra-
corporeal circuit. In 1958, Creech et al. [8] employed the
technique in 24 patients with various malignant neoplasms,
and concluded that the administration of chemotherapeutic
agents by perfusion is useful for localized tumors and for
palliation of certain far-advanced lesions. As interest in
locoregional infusion techniques increased, treatment of
liver metastasis began to interest oncologists in the 1960s,
because it seemed that although the liver is a primary site
of blood-borne metastases, it is often the only site of
metastatic disease, especially in patients with CRC.
While work with hepatic resection was proceeding,
other groups were beginning to look carefully at the
regional infusion of chemotherapy for liver metastases.
However, hepatic arterial catheterization sometimes pre-
sented difficulties because of the extent of the disease. In
1961, a simple method of catheterization of the hepatic
artery through the gastroepiploic and gastroduodenal
arteries was first described by Miller et al. [9], who were
the pioneers of the modern HAI technique. Since Watkins
[10] developed the portable chronometric infusion pump to
concentrate the administration of large doses of drugs to
the liver in 1963, extensive clinical experience with
Table 1 The history of implantable port systems
ecivedelbatnalpmIyreviledgurDyparehtlanoigerocoL
Intra-arterial regional therapy Intra-arterial administration 
with nitrogen mustard of heparin, antibiotics
Klopp (1950) Donovan (1949)
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regional infusion chemotherapy of hepatic tumors has been
reported [11, 12]. Figure 1 shows a miniature portable
chronometric infusion pump (Watkins USCI Chronofusor;
United States Catheter & Instrument Corp., Glens Falls,
New York) developed by Watkins et al. [10, 13]. Most
experiences have involved percutaneously placed hepatic
artery catheters connected to extracorporeal pumps. How-
ever, these systems have been associated with mechanical
and infectious complications [14]. In the 1970s, a reliable,
totally implantable device was developed for long-term
intravascular drug infusion [14, 15]. The initial application
of the pump was for long-term heparin infusions in patients
with refractory thromboembolic disease [16]. With regard
to cancer therapy, regional infusion of chemotherapy for
liver metastases was expected to be oncologically useful.
Thus, HAI chemotherapy for liver metastases from CRC
became widely adopted in the 1980s.
HAI chemotherapy for CRC
Rationale for HAI
The rationale for hepatic arterial therapy is based on the
fact that once liver metastases grow beyond 3 mm, they are
fed predominantly by the hepatic artery, whereas normal
hepatocytes are fed predominantly by the portal vein [17].
The liver may be the initial stop for metastatic spread
through the portal vein, and early postoperative regional
administration of chemotherapeutic agents into the portal
vein might be particularly beneficial, destroying suspected
tumor cells in the liver before established tumor growth can
take place. However, from 1980 until the 1990s, several
randomized trials failed to show significant differences in
the survival benefit between portal vein infusion and sys-
temic chemotherapy after curative surgery for advanced
CRC [18–20].
Clinical evidence of HAI chemotherapy for CRC
On the other hand, HAI for liver metastases from CRC was
widely used based on several lines of evidence during the
same period. HAI therapy is associated with not only anti-
tumor effects, but also hepatic toxicity, and extensive
studies have been performed to identify the optimal agents.
Agents that are taken up by the liver and have high first-
pass extraction, as well as high total-body clearance, are
the most useful agents. The most active drug was shown to
be 5-fluoro-2-deoxyuridine (FUDR), which has a 60–90 %
first-pass liver extraction rate and an estimated 100- to
400-fold increase in hepatic exposure when used for HAI
[21]. Several randomized trials from the 1980s to 2000
were performed to compare HAI using FUDR with sys-
temic chemotherapy for unresectable liver metastases from
CRC. The results suggested that HAI using FUDR was
well tolerated and associated with a significantly better
response rate compared with systemic chemotherapy using
5-FU in the treatment of metastases from CRC, although
the survival benefit was limited. A meta-analysis combin-
ing the results of seven trials also supported the use of HAI
using FUDR in the treatment of unresectable liver metas-
tases from CRC [22]. A significantly higher response rate
of 41 % was obtained with HAI using FUDR compared
with a 14 % response rate with systemic 5-FU. In these
previous reports, the median survival was significantly
increased to 16 months with HAI versus 13 months with
systemic treatment.
Multimodal therapy using HAI for unresectable liver
metastases
The hepatic resection criteria have been expanded with
advances in surgical techniques; however, only 15–20 % of
patients have disease that is suitable for resection at the
time of presentation [23]. However, a proportion of tumors
may become resectable after they respond to preoperative
chemotherapy. Patients with potentially resectable liver
metastases are now treated with conversion therapy using
modern systemic chemotherapy, often a triple-drug cyto-
toxic regimen with molecular targeted agents, to maxi-
mally downsize the disease and subsequently facilitate
curative surgical resection of the metastases [24, 25]. The
conversion strategy stems from HAI therapy for liver
metastases from CRC. HAI is characteristic in that high
response rates can be achieved despite the fact that no
modern active agents can increase the resection rates for
Fig. 1 A chronometric ambulatory infusion apparatus. A disposable
plastic bag serves as a reservoir for a concentrated solution of drug.
Reprinted with permission from the American Association for Cancer
Research [13]
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initially unresectable liver metastases. Several studies have
shown the efficacy of neoadjuvant HAI chemotherapy in
patients with initially unresectable liver metastases from
CRC [26]. High response rates of 16–90 % using HAI
correlated with the complete hepatic resection rates. These
results suggest that both locoregional drug delivery and
optimization of the pharmacological effects are important
for metastatic CRC therapy.
Pharmacokinetics of HAI chemotherapy
The pharmacokinetics of 5-FU are influenced by the dose
and schedule of administration. Short-term, high-concen-
tration exposures are thought to favor RNA-directed 5-FU
toxicity, whereas DNA-directed effects are felt to be more
prominent with longer exposures to lower drug concen-
trations [27–29]. These pathways are not mutually exclu-
sive, and more than one mechanism of action may
contribute to cytotoxicity. This may support the recent
standard intravenous 5-FU regimens comprising bolus plus
infusional 5-FU in combination with leucovorin, derived
from the DeGramont regimen [30]. Kusunoki et al. [31]
reported another promising approach using oral fluoro-
pyrimidines as pharmacokinetic modulating chemotherapy,
the pharmacokinetic concept of which resembled that of
the DeGramont regimen.
The concept of pharmacokinetic modulation is that the
benefit of a continuous 5-FU infusion could be potentiated
by low-dose oral uracil/tegafur (UFT), and the wide varia-
tion of 5-FU concentrations in each patient requires an
implantable port system to achieve optimal concentrations.
This pharmacokinetic modulating chemotherapy regimen
has been proven to be highly effective for treating CRC [31,
32]. Its efficacy is based on the fact that the pharmacokinetic
modulation targets at least two different phases of the cell
cycle, depending on the dose of 5-FU [33]. HAI efficacy and
other problems in patients with CRC with liver metastases
have also been reported from a pharmacokinetic viewpoint
[34]. In one study, HAI via an implantable port system
comprised perfusion 5-FU for two consecutive days per
week at 600 mg/m2/day and oral administration of UFT at
400 mg/day. HAI using pharmacokinetic modulating che-
motherapy significantly decreased the incidence of hepatic
recurrence after curative resection, but not the incidence of
lung recurrence [34]. The authors stated that the maximum
plasma concentration of 5-FU in the HAI group reached
144 ng/mL, which was lower than the 400 ng/mL reached
in the systemic chemotherapy group, and discussed how the
pharmacokinetics might lead to an oncological limitation of
locoregional therapy. In other words, HAI chemotherapy
might have an important role as an oncological strategy
when combined with modern systemic chemotherapy or
when used as part of multimodal therapy.
Development of port devices
Implantable port devices for HAI
The implantable port device was originally described in
1963 by Ommaya [35, 36] as a cerebrospinal fluid reservoir
and manual pump (Fig. 2). The device was introduced to
facilitate repeated injections of drugs into the cerebrospinal
fluid of patients with fungal meningitides [37]. The device
subsequently proved to be of considerable mechanical
value in the treatment of malignant neoplasms of the ner-
vous system by allowing the perfusion and instillation of
cytotoxic agents [38, 39]. An implantable pump system
that allows for continuous infusion of drugs, including
heparin, was developed in 1972 [40]. The pump was a
titanium disc about the size and shape of a small ice hockey
puck (Fig. 3). The hollow titanium disc was divided into
two chambers by a flexible titanium bellows. The first use
of this device to deliver chemotherapeutic agents to hepatic
tumors was reported in 1980 [41]. It proved very reliable,
without mechanical complications, and was rarely subject
to the problems seen with percutaneously placed catheters
that are left in place for prolonged infusion. After the
implantable port device went into production in the 1970s,
HAI was more commonly performed.
The development of the non-battery-powered mecha-
nism for a totally implantable HAI pump allowed for the use
of HAI as a long-term therapy. In 1980, Cohen et al. [42]
reported transbrachial hepatic arterial chemotherapy using a
modern implantable infusion pump. The Infusaid
implantable pump (Metal Bellows Corporation, Sharon,
Fig. 2 A diagram of a cerebrospinal fluid reservoir connected to the
lateral ventricle, showing the method of use. Reprinted with
permission from the Massachusetts Medical Society [36]
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Massachusetts) was a hockey-puck-sized (9 cm in diameter,
2 cm thick) titanium shell encasing welded titanium. The
implantable pump had a 50-cm3 reservoir and a side port by
which one could directly inject drugs into the catheter. The
basic design of the pump was a two-chambered unit made of
titanium [43] (Fig. 4). One chamber was a drug fluid
chamber that could be accessed from the outside of the
pump. The other chamber was charging fluid chamber that
was filled with Freon. The mechanism driving the pump
involved mechanical energy that was supplied during each
refill of the pump. The fluid to fill the pump would be placed
into the drug chamber by means of a percutaneously placed
needle. This would fill up the drug chamber and push out the
bellows that compressed the charging chamber. The com-
pressed Freon would also expand with body heat, then exert
its energy by pushing up on the diaphragm in the device,
which would slowly push fluid out through the catheter of
the pump. After the Infusaid implantable pump was
developed, other pump designs with different mechanisms
appeared to further miniaturize these devices, some of
which could only be accessed from the central needle inlet
[44]. The Codman Constant Flow Infusion Pump was
designed with a raised septum at the center of the device
that can be easily palpated through the skin, making the
refill septum more accessible (Fig. 5). This also allowed for
much easier detection should a pump invert within the
pocket. The safety of use and the efficacy of treatment for
regional chemotherapy and pain control were reported
previously [45–48].
HAI treatment was initially performed by means of a
catheter that was surgically placed in the hepatic artery
after isolation of the gastroduodenal artery, and the catheter
was then connected to the port placed in a subcutaneous
pocket [49, 50]. To access the artery more easily, Arai et al.
[51] reported a radiological method with which to place an
implantable catheter by surgical cut-down of the small
branch of the subclavian artery in 1982. In 1990, Kumada
et al. [52] also reported a technique created by modifying
Arai’s method so that arterial access could be directly
obtained under sonographic guidance. These minimally
invasive ways of implanting an infusion catheter for che-
motherapy contributed to the widespread use of HAI
treatment for liver metastases from CRC.
Central venous port systems
Historically, implantable port systems were developed
without distinction between hepatic arterial or central
venous access. However, there was a difference in the
original aim of drug delivery systems between HAI and
central venous access. Whereas HAI via implantable port
systems was developed for long-term oncological treat-
ment, central venous port systems were developed for
several reasons, including repeated administration of che-
motherapeutic agents, parental nutrition, transfusions,
infusions, injections and/or blood sample collection. Con-
sequently, central venous port systems play a key role in
modern oncology, especially in chemotherapy for patients
Fig. 3 An implantable infusion pump. Dimensions: 2.82 cm
height 9 8.43 cm diameter. The empty weight was 184 g. This
material is reproduced with the permission of the American Cancer
Society and John Wiley & Sons, Inc [41]
Fig. 4 A cross-sectional
diagram of the Infusaid pump.
Reprinted with permission from
the American Diabetes
Association [43]
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with metastatic CRC. Frequent puncturing of peripheral
veins and the local effects of chemotherapeutic drugs cause
damage, thrombosis and sclerosis of vascular walls, and the
use of port systems for permanent central venous access
allows patient to continue long-term treatment.
The first central venous catheters developed were per-
cutaneous, non-tunneled catheters, which came into use in
the 1950s [53]. The first long-term central venous catheter
was used for parenteral nutrition in 1973 [54]. With regard
to oncological use, the Hickman [55] catheter, a long-term
venous access device, was used for chemotherapy for the
first time in 1979. Open, tunneled central venous catheter
systems, such as the Hickman catheter, are associated with
a higher infection rate because the end of the catheter
remains outside the body. Implantable port systems have
advantages in that the puncturing needle can be removed
after each injection, and the skin covering the port serves as
a natural protection against infection. The currently used
central venous port system was introduced to clinical use in
1982 by Niederhuber et al. [56]. The device, an injection
port (Infuse-A-Port; Infusaid Corp., Sharon, Massachu-
setts), comprises a 3.5 9 1.5 cm conical chamber with a
self-sealing silicon rubber septum connected to a Silastic
catheter. This totally implanted venous and arterial access
system was initially tested in 30 patients with cancer. A
variety of anticancer agents was administered without
difficulty, and patient acceptance was excellent.
The Infuse-A-Port had advantages in terms of its size
and cost compared with the above-mentioned Infusaid
implantable pump with its complex mechanism. In the
early 1980s, both the Infuse-A-Port and Infusaid
implantable pumps were introduced in Japan by Miura
et al. [57]. Over the last few decades, central venous port
systems have been implanted during minimally invasive
procedures by surgeons or interventional radiologists.
Implantable central venous port systems therefore facilitate
safe and easy blood access in oncology today, although
several relevant long-term complications exist, as descri-
bed below.
Complications associated with central venous ports
There are several important complications associated with
central venous ports [58, 59]. Port complications can be
subdivided into procedural complications, catheter-related
complications and vascular complications. Short-term
complications include accidental arterial puncture, hema-
toma, air embolism, pneumothorax or vessel perforation
[60], but these complications are rare in modern oncology.
Surgical complications arise in \2 % of cases in experi-
enced hands [61]. Clinical oncologists are currently most
often concerned with major long-term complications
associated with the use of catheters in chemotherapy. A
retrospective study by Yildizeli et al. [62] showed that
among 225 implantable port systems, the long-term com-
plications included infection (2.2 %), thrombosis (1.3 %),
extravasation (1.3 %) and catheter fracture (2.2 %). The
major long-term problems of catheter use in patients with
cancer are catheter-related infection and thromboembolic
complications. Both complications may lead to significant
morbidity and impairment of the patient’s quality of life.
The catheter-related infection rates in recent studies
ranged from 0.8 to 7.5 % [63, 64]. The incidence of
catheter-associated thrombosis in patients with cancer
varies considerably between studies and patient or cancer
type, with the incidence of catheter-associated thrombosis
among several studies varying widely from 12 to 64 %
[65–69]. Several researchers evaluated the benefit of anti-
coagulant prophylaxis with either low molecular weight
heparin or warfarin in patients with cancer using central
venous devices; however, routine anticoagulation cannot
be recommended [69–73].
Importance of pharmacokinetics in the chemotherapy
for CRC
Even in modern chemotherapy using several active agents,
5-FU plays a central role in the treatment of CRC, and
many attempts have been made to improve its efficacy and
potentiate its action over the last 50 years. In particular,
recent reports suggested that the pharmacokinetics of 5-FU
remain an important factor that affects the prognosis of
patients with CRC, even after the introduction of modern
chemotherapy for CRC [74–77]. An implantable port sys-
tem is indispensable in both HAI and central venous port
systems to optimize the pharmacokinetics in multiagent
chemotherapy. This is important, because the treatment of
advanced CRC increasingly requires a multimodal
approach. A recent trend highlights the possibility of using
Fig. 5 A schematic diagram of an implantable pump. Reprinted with
permission from Elsevier Ltd. [44]
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active first-line chemotherapy to affect the downstaging of
metastases and so enable curative surgery for initially un-
resectable disease, especially liver metastases from CRC
[24, 25, 78]. From a pharmacological viewpoint, both dose-
and time-dependent administration of chemotherapeutic
agents is possible via implantable port systems, thus
resulting in high response rates in many situations.
On the other hand, recent attention has been given to port-
free chemotherapy using oral fluoropyrimidines, such as
capecitabine, because of their convenience. Capecitabine is a
unique fluoropyrimidine carbamate that is selectively con-
verted to 5-FU in tumors through a cascade involving three
enzymes [79]. Using a rational design and taking advantage
of the unique tissue localization patterns of these key
enzymes, capecitabine was developed to be selectively
activated within tumor tissues. Indeed, CapeOx with bev-
acizumab as port-free chemotherapy showed high response
rates ranging from 50 to 78 % and a high conversion rate of
40 % for initially unresectable hepatic metastases [80, 81].
However, recent evidence shows that there are few choices
regarding port-free chemotherapy, especially first-line che-
motherapy, for advanced or metastatic CRC. Besides Ca-
peOx with bevacizumab, the other recommendations for
first-line chemotherapy for advanced or metastatic CRC in
the NCCN guidelines include FOLFOX ± bevacizumab,
FOLFIRI ± bevacizumab, FOLFIRI ± ant-EGFR anti-
body, 5-FU ? leucovorin ? bevacizumab and FOLFOX-
IRI; all require central venous port systems [82].
Conclusion
Modern chemotherapy using various combinations of regi-
mens for advanced CRC became widely accepted with the
development of the implantable port system. Historically,
chemotherapy using implantable port systems was begun for
the purpose of locoregional cancer therapy to obtain further
oncological benefits. This concept resembles that of modern
chemotherapy, which aims to optimize the pharmacokinetics
of chemotherapeutic agents. The treatment of advanced CRC
increasingly requires a multimodal approach and multiple
treatment options, which are based not only on convenience,
but especially on personalization and efficacy. Implantable
port systems for CRC have been essential for oncological
practice, and the oncologic importance of these systems will
remain unchanged in the near future.
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